The genetic causes of cancer result in dysregulation of a wide variety of cellular pathways. Owen Witte, MD, and his collaborators were among the first to characterize oncogenic kinase activation in leukemia with the discoveries of the BCR-ABL fusion and BTK genes, leading to the development of several early targeted therapies. “The idea that you could be so selective to hit the single causative agent or genetic change in a cancer really opened a whole new world,” he said. Witte's discoveries have been recognized by this year's AACR Award for Outstanding Achievement in Blood Cancer Research. As a University Professor at the University of California, Los Angeles, and the founding Director Emeritus of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research, Witte's current work focuses on the identification of targets and development of immunotherapies for solid epithelial cancers. He spoke with Blood Cancer Discovery's...
Skip Nav Destination
Article navigation
1 May 2024
News in Depth|
May 01 2024
Q&A: Owen Witte on Translational Research in Cancer
Online ISSN: 2643-3249
Print ISSN: 2643-3230
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
Blood Cancer Discov (2024) 5 (3): 136–138.
Citation
Q&A: Owen Witte on Translational Research in Cancer. Blood Cancer Discov 1 May 2024; 5 (3): 136–138. https://doi.org/10.1158/2643-3230.BCD-24-0069
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
77
Views
Citing articles via
Advertisement